BICO Receives Additional Order From Walter Reed For Rapid HIV Tests
PITTSBURGH, Oct. 2 /PRNewswire/ -- BICO, Incorporated (OTC Bulletin Board: BIKO) announced today that subsidiary Rapid HIV Detection Corp. has received an order for an additional 1,200 of its InstantScreen(R) Rapid HIV tests from Walter Reed Army Institute of Research in Washington, DC for use in scientific evaluation.
In August, Walter Reed Institute placed an order for 14,000 InstantScreen tests for further evaluation by its HIV Research Program after a previous Walter Reed study of 592 InstantScreen tests demonstrated 100% accuracy. This InstantScreen data was presented to the National HIV Prevention Conference in Atlanta, Georgia in August as part of Walter Reed Institute's larger study of rapid HIV tests.
The 1,200 tests were delivered to Walter Reed last week.
BICO recently acquired the exclusive worldwide marketing rights to InstantScreen, which was developed and is manufactured by the German American Institute for Applied Research (GAIFAR) in Potsdam, Germany.
InstantScreen delivers results in 5-30 seconds, requires no special training, no extra equipment or refrigeration, and uses only a small amount of finger prick blood. A positive result of the InstantScreen can be verified within minutes with InstantConfirm(R), the first and only test to transform the gold-standard laboratory confirmation test into a rapid format for use at the test site.
In combined documented studies by institutions such as Walter Reed Army Institute; Noguchi Memorial Institute for Medical Research in Accra, Ghana; World Health Organization; and the National Institute for Virology in South Africa, InstantScreen has demonstrated 100% specificity and 100% sensitivity.
Initially, InstantScreen will be marketed outside the US, especially in Africa, India, South America, the Caribbean and Asia, where HIV/AIDS is rampant. GAIFAR will concurrently seek FDA approval.
BICO has its corporate offices in Pittsburgh, PA and is involved in the development and manufacture of biomedical devices and environmental solutions. Subsidiary Rapid HIV Detection Corp. is also located in Pittsburgh, PA US, Washington, DC US, and Accra, Ghana Africa.
This press release contains statements of a forward-looking nature. Shareholders and potential investors are cautioned that such statements are predictions and actual events or results may vary significantly.
FOR FURTHER INFORMATION, CONTACT:
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
www.bico.com
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE BICO, Incorporated
/CONTACT: Investors: Diane McQuaide, +1-412-429-0673, or fax:
+1-412-279-9690; or Media: Susan Taylor, +1-412-429-0673, or fax:
+1-412-279-5041, both of BICO/
/Web site: bico.com / |
